logo UCSF Benioff Children's Hospital Oakland
Hematology/Oncology Department
Research Studies Open for Enrollment
Date: 12/12/2018

Oncology:

Title ID/Protocol NCT/Phase Sponsor P.I. Contact
ONCOLOGY
Pediatric Tissue Bank at the Children's Hospital & Research Center OaklandONC Tissue Bank N/A
Jon Rowland, MD
The Effectiveness of Lactobacillus plantarum (LBP, IND# 17339) in Preventing Acute Graft-versus-Host Disease (GvHD) in Children undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)ACCL1633 N/A
Phase 3
Children's Oncology Group (COG)Carla Golden, MDChristine Ho (510-428-3885 x 2609)
Solid Tumors
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)AHEP1531 N/A
Phase 3
Children's Oncology Group (COG)Carla Golden, MDChristine Ho (510-428-3885 x 2609)
ONCOLOGY: EARLY PHASE
Leukemia, Lymphoma
Pilot Study of Mitoxantrone in combination with Clofarabine in Children, Adolescents and Young Adults with Refractory/Relapsed Acute Leukemia or High Grade Non-Hodgkin LymphomaMITCL NCT01842672
Phase 1/2a
New York Medical CollegeJennifer Michlitsch, MDAnu Agrawal, MD (510-428-3885 x3539)
Lymphoma
Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35), or Crizotinib (commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell LymphomaANHL12P1 NCT01979536
Phase 2
Children's Oncology GroupCarla Golden, MDChristine Ho (510-428-3885 x 2609)
Risk adapted, response based trial of nivolumab and brentuximab vedotin followed by brentuximab vedotin and bendamustine for pediatric and young adults with relapsed or refractory CD30 positive classic Hodgkin lymphomaAHOD1721 NCT02927769
Phase 2
Children's Oncology GroupCarla Golden, MDChristine Ho (510-428-3885 x 2609)
Lymphoma, Solid Tumors
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of JNJ-42756493 (Erdafitinib) in patients with tumors harboring FGFR1/2/3/4 alterationsAPEC1621B NCT03210714
Phase 2
Children's Oncology GroupCarla Golden, MDChristine Ho (510-428-3885 x 2609)
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of LOXO-101 (larotrectinib) in patients with tumors harboring actionable NTRK fusionsAPEC1621A NCT03213704
Phase 2
Children's Oncology GroupCarla Golden, MDChristine Ho (510-428-3885 x 2609)
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of LY3023414 in Solid TumorsAPEC1621D NCT03155620
Phase 2
Children's Oncology GroupCarla Golden, MDChristine Ho (510-428-3885 x 2609)
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of olaparib in patients with tumors harboring defects in DNA damage repair genesAPEC1621H NCT03233204
Phase 2
Children's Oncology GroupCarla Golden, MDChristine Ho (510-428-3885 x 2609)
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of tazemetostat for patients with tumors harboring alterations in EZH2 or members of the SWI/SNF complexAPEC1621C NCT03213665
Phase 2
Children's Oncology GroupCarla Golden, MDChristine Ho (510-428-3885 x 2609)
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterationsAPEC1621F NCT03213652
Phase 2
Children's Oncology GroupCarla Golden, MDChristine Ho (510-428-3885 x 2609)
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Vemurafenib in patients with tumors harboring actionable BRAF V600 mutationsAPEC1621G NCT03220035
Phase 2
Children's Oncology GroupCarla Golden, MDChristine Ho (510-428-3885 x 2609)
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice): Phase 2 subprotocol of Selumetinib in patients with Tumors harboring activating MAPK pathway mutationsAPEC1621E NCT03213691
Phase 2
Children's Oncology GroupCarla Golden, MDChristine Ho (510-428-3885 x 2609)
Solid Tumors
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle GenesAPEC1621I N/A
Phase 2
Children's Oncology GroupCarla Golden, MDChristine Ho (510-428-3885 x 2609)
Neuroblastoma Maintenance Therapy Trial Using DifluoromethylornithineNMTRC-014-DFMO NCT02679144
Phase 2
Beat Childhood Cancer (BCC)Anu Agrawal, MDAnu Agrawal, MD (510-428-3885 x3539)
Pazopanib in Combination with Irinotecan and Temozolomide for Children and Young Adults with Relapsed or Refractory SarcomaPAZIT NCT03139331
Phase 1
University of California, San FranciscoJennifer Michlitsch, MDAnu Agrawal, MD (510-428-3885 x3539)
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare TumorsADVL1622 NCT02867592
Phase 2
Children's Oncology GroupCarla Golden, MDChristine Ho (510-428-3885 x 2609)
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing SarcomaAEWS1221 NCT02306161
Phase 3
Children's Oncology GroupCarla Golden, MDChristine Ho (510-428-3885 x 2609)
Two-Part Study of TB-403 in Pediatric Subjects with Relapsed or Refractory Medulloblastoma, Neuroblastoma, Ewing Sarcoma or Alveolar RhabdomyosarcomaTB-403 NCT02748135
Phase 1/2a
Beat Childhood Cancer (BCC) and Oncurious NVJennifer Michlitsch, MDJennifer Michlitsch, MD (510-428-3885 x3264)
STEM CELL TRANSPLANTATION AND CELLULAR THERAPY
Oncology
Role of KIR-favorably Mismatched Haploidentical Transplantation and KIR-polymorphisms in Determining Outcomes of Children with ALL/AML/MDS Undergoing Allogeneic Hematopoietic Cell TransplantationONC1401 NCT02646839
Phase 1/2
Pediatric Blood and Marrow Transplatn ConsortiumNahal Rose Lalefar, MDMarci Moriarty, RN (510-428-3385 x5396)
Oncology: Early Phase, Leukemia
Pediatric and Young Adult Leukemia Adoptive Therapy. A Phase 1/2 Feasibility and Safety Study of CD19-CAR T Cell Immunotherapy for CD19+ LeukemiaPLAT-02 NCT02028455
Phase 1/2
Seattle Children's HospitalAnu Agrawal, MDMarci Moriarty, RN (510-428-3385 x5396)

UCSF Benioff Children's Hospital Oakland • 747 52nd Street, Oakland, California 94609 • Phone: (510) 428-3000